Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (NASDAQ: PCRX) reported Q3 2025 revenues of $179.5M and updated full-year guidance on November 6, 2025. The company raised its full-year non-GAAP gross margin to 80–82% and reiterated other ranges while narrowing total revenue to $725M–$735M. Q3 results included EXPAREL net sales of $139.9M (volume +9%), adjusted EBITDA of $49.4M, GAAP net income of $5.4M (EPS $0.12), and non-GAAP net income of $31.8M (EPS $0.72 basic). Pacira repurchased 2.0M shares for $50.0M, ended the quarter with $246.3M cash, completed enrollment in Part A of its Phase 2 ASCEND PCRX-201 study, and in‑licensed AMT-143 under a deal with a $5.0M upfront payment.

Pacira BioSciences (Nasdaq: PCRX) announced it has concluded patient enrollment in Part A of the Phase 2 ASCEND study of PCRX-201 for osteoarthritis of the knee. Part A randomized ~45 patients 1:1:1 to two dose levels (1.4×10¹⁰ GC and 1.4×10¹¹ GC) or saline, with steroid pretreatment for all cohorts. The study will enroll ~135 patients across Parts A and B; Part B will randomize ~90 patients using commercial-scale manufactured drug product. The primary endpoint is safety through Week 52; secondary endpoints include pain and function at Weeks 38 and 52 (NRS, WOMAC, KOOS). Pacira expects topline Part A results before the end of 2026 and will follow participants for five years.

Pacira BioSciences (NASDAQ: PCRX) entered an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a long-acting formulation of ropivacaine for postsurgical pain control.

The company said AMT-143 complements EXPAREL, advances Pacira's 5x30 pipeline strategy, and has a Phase 2 program expected to begin in 2026. Management indicated the asset could be meaningfully accretive to cash flow and earnings within the 5x30 timeframe.

Pacira (Nasdaq: PCRX) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a live conference call and webcast at 4:30 p.m. ET following the release.

Investors who wish to ask questions by phone must pre-register to receive dial-in details and a PIN. A live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible on the Pacira website for about two weeks after the call.

Pacira BioSciences (NASDAQ: PCRX) reported updated three-year results from its open-label Phase 1 trial of PCRX-201 for moderate-to-severe osteoarthritis of the knee. A single ultrasound-guided intra-articular injection at each of three dose levels was well tolerated and produced sustained, clinically meaningful reductions in pain and stiffness and improvements in function through 156 weeks in 72 patients across two cohorts.

Key findings include no serious treatment-related adverse events, lower treatment-related index joint effusion rates with corticosteroid pretreatment (42% vs 67%), pre-existing anti-AD5 neutralizing antibodies did not affect outcomes, and results support a Phase 2 ASCEND strategy using a 10-fold lower dose (1.4E11 GC) with corticosteroid pretreatment. Findings were presented at ACR Convergence 2025.

Pacira (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice from Qilu Pharmaceutical (Hainan) Co., Ltd., which filed an ANDA with the FDA seeking approval of a generic version of EXPAR EL. Qilu alleges invalidity or noninfringement of 18 Orange Book-listed patents (U.S. Patent Nos. 11,033,495 through 12,370,142).

Pacira says the contested patents belong to two families expiring on January 22, 2041 and July 2, 2044. Pacira intends to enforce its IP and has 45 days to sue, which would trigger an automatic 30‑month FDA stay on Qilu’s ANDA approval under Hatch‑Waxman.

Pacira BioSciences (NASDAQ: PCRX) will present new real-world and health-economic data for EXPAREL at the AMCP Nexus 2025 Annual Meeting, Oct 27–30 in National Harbor, MD. Presentations on Oct 29 (12:00–1:00 p.m. ET) include results from the multicenter prospective IGOR registry and three posters evaluating EXPAREL's association with pain, opioid use, function, length of stay, healthcare utilization, and costs in total knee and outpatient shoulder arthroplasty settings.

Abstracts are available in the Journal of Managed Care + Specialty Pharmacy supplement.

Pacira BioSciences (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice Letter from The WhiteOak Group, which filed an ANDA with the FDA claiming a generic version of EXPAREL.

WhiteOak disputes claims of 19 EXPAREL patents listed in the Orange Book and asserts they are invalid, unenforceable, or not infringed. Pacira identified two patent families with expiration dates of January 22, 2041 and July 2, 2044. Pacira has 45 days from receipt to sue; filing would trigger an automatic 30-month stay of FDA approval under Hatch-Waxman.